News Archives - Congruence

Congruence Therapeutics Announces Closing of $32M Financing to Advance First-in-Class Genetic Obesity Candidate Drug CGX-926 Through Phase 1b Proof of Concept Clinical Trial

https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime

By Araceli Richardson|2025-09-04T08:08:59-07:0009.04.2025|News|0 Comments

Congruence Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to Advance Novel GCase Activators and Correctors for Parkinson’s Disease with GBA1 Mutations

https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime

By Araceli Richardson|2025-07-24T06:04:11-07:0007.24.2025|News|0 Comments

Congruence Therapeutics Announces Oral Presentation on MC4R Corrector Development Candidate CGX-926 for Early-Onset Obesity at the 3rd Annual Obesity & Weight Loss Drug Development Summit

https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime

By Araceli Richardson|2025-07-16T06:02:55-07:0007.16.2025|News|0 Comments

Congruence Therapeutics Announces Oral Presentation on Novel GCase Activators and Correctors for Parkinson’s Disease with GBA1 Mutations at the GBA1 Meeting 2025

https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime

By Araceli Richardson|2025-06-03T06:07:21-07:0006.03.2025|News|0 Comments

Congruence Therapeutics Announces Participation at the Citi Biotech Private Access Day and 2025 Bloom Burton & Co. Healthcare Investor Conferences

https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime

By Araceli Richardson|2025-04-28T13:45:12-07:0004.22.2025|News|0 Comments

Congruence Therapeutics Announces Participation in the 24th Annual Needham Virtual Healthcare Conference

https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime

By Araceli Richardson|2025-03-26T13:10:27-07:0003.26.2025|News|0 Comments

Congruence and Ono Announce Multi-Target Research Collaboration to Generate Small Molecule Correctors for the Treatment of Cancer

https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime

By Araceli Richardson|2024-12-03T05:02:51-08:0012.03.2024|News|0 Comments

Congruence Therapeutics Announces Blitz Talk Award and Poster Presentations on MC4R-Deficient Genetic Obesity Program at Obesity Week 2024

https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime

By Araceli Richardson|2024-11-03T09:06:59-08:0011.03.2024|News|0 Comments

Congruence Therapeutics Announces Poster Presentation on Discovery of Novel GCase Correctors for Parkinson’s Disease with GBA1 mutations at the 2024 International Congress of Parkinson’s Disease and Movement Disorders Meeting

https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime

By Araceli Richardson|2024-09-27T06:05:30-07:0009.27.2024|News|0 Comments

Congruence Therapeutics Announces Participation in Upcoming Investor Conferences

https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime

By Araceli Richardson|2024-08-29T13:08:29-07:0008.29.2024|News|0 Comments